Search Results | Cancer Discovery | American Association for Cancer Research

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Cancer Discov (2022) 12 (7): 1676–1689.

DOI: https://doi.org/10.1158/2159-8290.CD-21-1615

Published: 06 July 2022

View article

Includes: Supplementary data

Journal Articles

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer

Cancer Discov (2022) 12 (1): 74–89.

DOI: https://doi.org/10.1158/2159-8290.CD-21-0715

Published: 01 January 2022

View article

Includes: Supplementary data

Journal Articles

FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma

Cancer Discov (2021) 11 (10): 2488–2505.

DOI: https://doi.org/10.1158/2159-8290.CD-20-1669

Published: 01 October 2021

View article

Includes: Supplementary data

Journal Articles

Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity

Cancer Discov (2021) 11 (8): 1952–1969.

DOI: https://doi.org/10.1158/2159-8290.CD-20-0913

Published: 01 August 2021

View article

Includes: Supplementary data

Journal Articles

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

Cancer Discov (2021) 11 (7): 1688–1699.

DOI: https://doi.org/10.1158/2159-8290.CD-20-1598

Published: 01 July 2021

View article

Includes: Supplementary data

Journal Articles

Targeting MET Dysregulation in Cancer

Gonzalo Recondo, Jianwei Che, Pasi A. Jänne, Mark M. Awad

Cancer Discov (2020) 10 (7): 922–934.

DOI: https://doi.org/10.1158/2159-8290.CD-19-1446

Published: 01 July 2020

View article

Journal Articles

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

Junji Tsurutani, Hiroji Iwata, Ian Krop, Pasi A. Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles Redfern, Kenji Tamura, Trisha M. Wise-Draper, Kaku Saito, Masahiro Sugihara, Jasmeet Singh, Takahiro Jikoh, Gilles Gallant, Bob T. Li

Cancer Discov (2020) 10 (5): 688–701.

DOI: https://doi.org/10.1158/2159-8290.CD-19-1014

Published: 01 May 2020

View article

Includes: Supplementary data

Journal Articles

The KRAS^G12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Cancer Discov (2020) 10 (1): 54–71.

DOI: https://doi.org/10.1158/2159-8290.CD-19-1167

Published: 09 January 2020

View article

Includes: Supplementary data

Journal Articles

Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor

Ciric To, Jaebong Jang, Ting Chen, Eunyoung Park, Mierzhati Mushajiang, Dries J.H. De Clercq, Man Xu, Stephen Wang, Michael D. Cameron, David E. Heppner, Bo Hee Shin, Thomas W. Gero, Annan Yang, Suzanne E. Dahlberg, Kwok-Kin Wong, Michael J. Eck, Nathanael S. Gray, Pasi A. Jänne

Cancer Discov (2019) 9 (7): 926–943.

DOI: https://doi.org/10.1158/2159-8290.CD-18-0903

Published: 01 July 2019

View article

Includes: Supplementary data

Journal Articles

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis, Michael E. Goldberg, Danielle M. Greenawalt, Matthew D. Hellmann, Mark M. Awad, Justin F. Gainor, Alexa B. Schrock, Ryan J. Hartmaier, Sally E. Trabucco, Laurie Gay, Siraj M. Ali, Julia A. Elvin, Gaurav Singal, Jeffrey S. Ross, David Fabrizio, Peter M. Szabo, Han Chang, Ariella Sasson, Sujaya Srinivasan, Stefan Kirov, Joseph Szustakowski, Patrik Vitazka, Robin Edwards, Jose A. Bufill, Neelesh Sharma, Sai-Hong I. Ou, Nir Peled, David R. Spigel, Hira Rizvi, Elizabeth Jimenez Aguilar, Brett W. Carter, Jeremy Erasmus, Darragh F. Halpenny, Andrew J. Plodkowski, Niamh M. Long, Mizuki Nishino, Warren L. Denning, Ana Galan-Cobo, Haifa Hamdi, Taghreed Hirz, Pan Tong, Jing Wang, Jaime Rodriguez-Canales, Pamela A. Villalobos, Edwin R. Parra, Neda Kalhor, Lynette M. Sholl, Jennifer L. Sauter, Achim A. Jungbluth, Mari Mino-Kenudson, Roxana Azimi, Yasir Y. Elamin, Jianjun Zhang, Giulia C. Leonardi, Fei Jiang, Kwok-Kin Wong, J. Jack Lee, Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba, Vincent A. Miller, Garrett M. Frampton, Jedd D. Wolchok, Alice T. Shaw, Pasi A. Jänne, Philip J. Stephens, Charles M. Rudin, William J. Geese, Lee A. Albacker, John V. Heymach

Cancer Discov (2018) 8 (7): 822–835.

DOI: https://doi.org/10.1158/2159-8290.CD-18-0099

Published: 01 July 2018

View article

Includes: Supplementary data

Journal Articles

Acquired MET^D1228V Mutation and Resistance to MET Inhibition in Lung Cancer

Magda Bahcall, Taebo Sim, Cloud P. Paweletz, Jyoti D. Patel, Ryan S. Alden, Yanan Kuang, Adrian G. Sacher, Nam Doo Kim, Christine A. Lydon, Mark M. Awad, Michael T. Jaklitsch, Lynette M. Sholl, Pasi A. Jänne, Geoffrey R. Oxnard

Cancer Discov (2016) 6 (12): 1334–1341.

DOI: https://doi.org/10.1158/2159-8290.CD-16-0686

Published: 04 December 2016

View article

Includes: Supplementary data

Journal Articles

Progress on Covalent Inhibition of KRAS^G12C

Kenneth D. Westover, Pasi A. Jänne, Nathanael S. Gray

Cancer Discov (2016) 6 (3): 233–234.

DOI: https://doi.org/10.1158/2159-8290.CD-16-0092

Published: 06 March 2016

View article

Journal Articles

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer

Erin M. Tricker, Chunxiao Xu, Sharmeen Uddin, Marzia Capelletti, Dalia Ercan, Atsuko Ogino, Christine A. Pratilas, Neal Rosen, Nathanael S. Gray, Kwok-Kin Wong, Pasi A. Jänne

Cancer Discov (2015) 5 (9): 960–971.

DOI: https://doi.org/10.1158/2159-8290.CD-15-0063

Published: 01 September 2015

View article

Includes: Supplementary data

Journal Articles

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

Cancer Discov (2013) 3 (12): 1355–1363.

DOI: https://doi.org/10.1158/2159-8290.CD-13-0310

Published: 10 December 2013

View article

Includes: Supplementary data

Journal Articles

Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in LKB1-Mutant Lung Cancer

Cancer Discov (2013) 3 (8): 870–879.

DOI: https://doi.org/10.1158/2159-8290.CD-13-0015

Published: 07 August 2013

View article

Includes: Supplementary data

Journal Articles

Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors

Cancer Discov (2012) 2 (10): 934–947.

DOI: https://doi.org/10.1158/2159-8290.CD-12-0103

Published: 14 October 2012

View article

Includes: Supplementary data

Journal Articles

Circumventing Cancer Drug Resistance in the Era of Personalized Medicine

Levi A. Garraway, Pasi A. Jänne

Cancer Discov (2012) 2 (3): 214–226.

DOI: https://doi.org/10.1158/2159-8290.CD-12-0012

Published: 13 March 2012

View article

Journal Articles

Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung Cancers

Hiu Wing Cheung, Jinyan Du, Jesse S. Boehm, Frank He, Barbara A. Weir, Xiaoxing Wang, Mohit Butaney, Lecia V. Sequist, Biao Luo, Jeffrey A. Engelman, David E. Root, Matthew Meyerson, Todd R. Golub, Pasi A. Jänne, William C. Hahn

Cancer Discov (2011) 1 (7): 608–625.

DOI: https://doi.org/10.1158/2159-8290.CD-11-0046

Published: 13 December 2011

View article

Includes: Supplementary data

Journal Articles

Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

Peter S. Hammerman, Martin L. Sos, Alex H. Ramos, Chunxiao Xu, Amit Dutt, Wenjun Zhou, Lear E. Brace, Brittany A. Woods, Wenchu Lin, Jianming Zhang, Xianming Deng, Sang Min Lim, Stefanie Heynck, Martin Peifer, Jeffrey R. Simard, Michael S. Lawrence, Robert C. Onofrio, Helga B. Salvesen, Danila Seidel, Thomas Zander, Johannes M. Heuckmann, Alex Soltermann, Holger Moch, Mirjam Koker, Frauke Leenders, Franziska Gabler, Silvia Querings, Sascha Ansén, Elisabeth Brambilla, Christian Brambilla, Philippe Lorimier, Odd Terje Brustugun, Åslaug Helland, Iver Petersen, Joachim H. Clement, Harry Groen, Wim Timens, Hannie Sietsma, Erich Stoelben, Jürgen Wolf, David G. Beer, Ming Sound Tsao, Megan Hanna, Charles Hatton, Michael J. Eck, Pasi A. Janne, Bruce E. Johnson, Wendy Winckler, Heidi Greulich, Adam J. Bass, Jeonghee Cho, Daniel Rauh, Nathanael S. Gray, Kwok-Kin Wong, Eric B. Haura, Roman K. Thomas, Matthew Meyerson

Cancer Discov (2011) 1 (1): 78–89.

DOI: https://doi.org/10.1158/2159-8274.CD-11-0005

Published: 01 June 2011

View article

Includes: Multimedia, Supplementary data

NARROW

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer

FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma

Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

Targeting MET Dysregulation in Cancer

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

The KRAS^G12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

Acquired MET^D1228V Mutation and Resistance to MET Inhibition in Lung Cancer

Progress on Covalent Inhibition of KRAS^G12C

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in LKB1-Mutant Lung Cancer

Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors

Circumventing Cancer Drug Resistance in the Era of Personalized Medicine

Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung Cancers

Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only